A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)Eun Joo Kang, KK Lee, Sang-Ho Lee et al.|ESMO Open|2024Cited by 10